What's Happening?
Xenon Pharmaceuticals has announced a voluntary hold on its psychiatry studies for azetukalner, its lead asset, following the emergence of psychosis adverse events in some patients. This decision led to a 23% drop in Xenon's shares. The psychosis events were
observed in trials for major depressive disorder (MDD) and bipolar depression, as well as in earlier epilepsy studies and healthy volunteers. Despite this, Xenon simultaneously submitted a new drug application (NDA) to the FDA for azetukalner in focal onset seizures (FOS), with a decision expected by September 2027. Chief Medical Officer Chris Kenney stated that the company views the pause as temporary and plans to make adjustments, including to the dosing schedule, which they believe could be contributing to the dose-dependent events. Analysts suggest the market reaction is overblown, noting similar adverse events are found in approved antidepressants.
Why It's Important?
This development highlights the complex challenges in developing drugs for neurological and psychiatric disorders, where side effect profiles can be particularly sensitive. While azetukalner shows significant promise for focal onset seizures, with a 42.7% placebo-normalized improvement in a Phase 3 trial and a potential $2 billion-plus market, the emergence of psychosis events in psychiatry trials raises concerns about its broader safety profile. The voluntary hold demonstrates Xenon's commitment to patient safety and regulatory compliance, but it also introduces uncertainty and delays for its psychiatric indications. The situation also brings attention to the broader class of KV7 potassium channel openers, as another company, Biohaven, recently faced a partial clinical hold for its similar asset. This could lead to increased scrutiny from regulatory bodies and investors regarding the safety of this drug class.
What's Next?
Xenon Pharmaceuticals will pause new enrollment in its MDD and bipolar depression trials for azetukalner and will make adjustments to the dosing schedule. The company expects to share more details on its revised plan in the coming months. The Phase 3 X-NOVA2 study in MDD will continue with its existing 360 patients, with a topline readout now anticipated in the first quarter of 2027. Meanwhile, the FDA will review the new drug application for azetukalner in focal onset seizures, with a decision expected by September 2027. The company will need to carefully manage the perception of its drug's safety profile, particularly as it seeks approval for its epilepsy indication, to reassure both regulators and the market that the psychosis events are manageable and not indicative of broader safety issues for the drug class.
Beyond the Headlines
The challenges faced by Xenon Pharmaceuticals with azetukalner underscore the intricate relationship between neurological and psychiatric conditions and the potential for drugs to have varied effects across different indications. The fact that psychosis events were observed in both epilepsy and psychiatric trials, albeit with varying incidence, suggests a complex interaction with neural pathways. This situation could lead to a deeper investigation into the mechanisms by which KV7 potassium channel openers affect brain function, potentially revealing new insights into the pathophysiology of both epilepsy and psychiatric disorders. The need for dose adjustments and careful monitoring for neuropsychiatric adverse events highlights the ongoing balance between efficacy and safety in drug development, particularly for central nervous system therapies. This event may also influence how regulatory bodies assess the safety of drugs with broad neurological activity, potentially leading to more stringent requirements for monitoring and risk mitigation strategies.
